Skip to main content
OpenTrials
Completed

NCT Number: NCT04596722

Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties

Pomegranate extract (Pomella) is well known for its antioxidant properties due to its phenolic compounds. It has also been shown to increase the amount of short chain fatty acid producing Lactobacillus and Bifidobacteria genera. Short chain fatty acids are thought to have an anti-inflammatory effect on the sebaceous glands. Previous studies have concluded that pomegranate extract may act as a prebiotic in the body and subsequently increasing the gastrointestinal microbial diversity and by producing short chain fatty acids that may have systemic beneficial effects especially on the skin.

Therefore, the aim of this study is to assess how Pomella alters the gut microbiome and the blood level of short chain fatty acids in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

25 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Integrative Skin Science and Research

Sacramento, California, 95815, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged 25-55
  • Must be willing to comply with all protocol requirements
  • Must be willing to have flash photo facial images taken with the imaging systems
  • Males must be willing to shave any facial hair

Exclusion criteria

  • Any systemic or antibiotics (injected or oral) within 6 months of starting study
  • Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide ingredient.
  • No intake of alcohol or tea throughout the duration of the study.
  • No more than 1 8 oz cup of coffee per week throughout the duration of the study.
  • No more than 1 cup of berries (strawberries, blueberries, raspberries, blackberries, etc.) per week throughout the duration of the study.
  • No intake of pomegranate, or pomegranate-containing drinks throughout the duration of the study.
  • No intake of chocolate (in any form) throughout the duration of the study.
  • No more than 1 cup of fermented dairy products per week throughout the duration of the study.
  • Any oral probiotic or prebiotic supplementation within past 1 month
  • Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis)
  • Has a condition or is on medication the investigator and/or designee believe could jeopardize the safety of the subject, interfere with the evaluation, or confound the interpretation of the study results
  • Women who have been pregnant in the last three months, are pregnant, preparing to be pregnant or lactating.
  • Is participating in a concurrent clinical research study or has participated in an acne or other facial study at this or any other facility in the past 4 weeks
  • Those with BMI higher than 35 kg/m²
  • Commencement of a new diet (such as the ketogenic diet) or supplements within the 1 month prior to initiating participation, at the discretion of the investigator.
  • Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic medications
  • Is participating in or has participated in a facial study at this or any other facility in the past 4 weeks. Participation in survey-based studies are approved at the discretion of the investigator.
  • Has a skin disease on face that will interfere with image collection and assessment in the opinion of the investigator
  • Refusal to shave or remove facial hair that may interfere with image collection and assessment.
  • Persons unwilling to avoid the following during the 4 weeks prior and during the duration of the study: self-tanning, spa tanning, sun tanning, or artificial tanning.
  • Planned vacation to sunny destination with the intention of sun tanning during the duration of the study.
  • Persons who regularly undergo sauna treatments (dry or wet) or who swim daily.
  • Known allergy or irritation to the supplement or facial products utilized in the study
  • Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5 year-pack year history of smoking tobacco
  • Prisoners
  • Adults unable to consent
  • Vegans

Treatment and study plan

Pomella

Dietary Supplement

Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size "1" capsules packed in white color HDPE bottle of 30 counts

Placebo

Other

White/white HPMC size "1" capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts

Primary outcomes

  1. Shift in Gut Microbiome Diversity

    Time frame: 4 weeks

    Stool is collected and analyzed for species of bacteria through nucleic acid sequencing.

Secondary outcomes

  1. Gut Microbiome Changes- Abundance and Presence of Short Chain Fatty Acid producing Bacteria

    Time frame: 4 weeks

    Stool is collected and analyzed for species of bacteria through nucleic acid sequencing.

  2. Safety Assessment for GI Distress

    Time frame: 4 weeks

    Subjective GI based Questionnaire that will assess for distress (one combined metric that accounts for stooling, gas, and discomfort)

  3. Change in Skin Brightness - Device based

    Time frame: 4 weeks

    SkinColorCatch colorimeter RGB range: 25-246 per channel

  4. Change in Sebum Excretion Rate

    Time frame: 4 weeks

    Delfin Sebumeter: 0-150 micrograms/cm^2

  5. Change in Transepidermal Water Loss

    Time frame: 4 weeks

    Delfin Vapometer 0-300g/m^2h; Delfin MoisturemeterSC 0-150

  6. Change in the Appearance of Facial Redness and Facial Skin Tone

    Time frame: 4 weeks

    SkinColorCatch colorimeter RGB range: 25-246 per channel; BTBP Clarity Mini 3D_V5 camera

  7. Shift in the Blood Short Chain Fatty Acid Levels

    Time frame: 4 weeks

    Short chain fatty acids are measured from a venipuncture

  8. Change in skin brightness - image based

    Time frame: 4 weeks

    BTBP Clarity Mini 3D Camera

Other outcomes

  1. Change in Skin Microbiome Diversity

    Time frame: 4 weeks

    The alpha and beta diversity of facial skin microbiome collections will be evaluated

Sponsors and collaborators

Lead sponsor

Integrative Skin Science and Research

Industry

Collaborators

  • Verdure Sciences

Registry information

Official study title

Prospective Randomized Double-Blind Placebo Controlled Study of Oral Pomella on the Microbiome and Skin Biophysical Properties

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Oct 22, 2020
Registry last updated
Apr 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.